Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Eyes $3.7M in Proceeds from Securities Purchase Deal

NEW YORK (GenomeWeb) – Interpace Diagnostics said after the close of the market on Tuesday that it has entered into a securities purchase deal with certain institutional investors that is expected to raise $3.7 million in net proceeds.

The investors have agreed to purchase 375,000 shares of Interpace's common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share. The offering is expected to close on or about Jan. 6.

Net proceeds from the deal will be used for working capital, repayment of debt, and general corporate purposes. Maxim Group served as the exclusive placement agent for the offering.

Interpace entered into a stock purchase deal last month to raise $1.7 million. The company also effected a 1-for-10 reverse stock split last week.

 

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.